These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33318007)

  • 1.
    Keating CL; Zuckerman JB; Singh PK; McKevitt M; Gurtovaya O; Bresnik M; Marshall BC; Saiman L
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
    McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB
    Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
    Oermann CM; McCoy KS; Retsch-Bogart GZ; Gibson RL; McKevitt M; Montgomery AB
    J Antimicrob Chemother; 2011 Oct; 66(10):2398-404. PubMed ID: 21784781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
    Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
    J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.
    Retsch-Bogart GZ; Burns JL; Otto KL; Liou TG; McCoy K; Oermann C; Gibson RL;
    Pediatr Pulmonol; 2008 Jan; 43(1):47-58. PubMed ID: 18041081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aztreonam lysine for inhalation solution: in cystic fibrosis.
    Plosker GL
    Drugs; 2010 Oct; 70(14):1843-55. PubMed ID: 20836577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes.
    Pesaturo KA; Horton ER; Belliveau P
    Ann Pharmacother; 2012; 46(7-8):1076-85. PubMed ID: 22764322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of inhaled aztreonam on the cystic fibrosis lung microbiome.
    Heirali AA; Workentine ML; Acosta N; Poonja A; Storey DG; Somayaji R; Rabin HR; Whelan FJ; Surette MG; Parkins MD
    Microbiome; 2017 May; 5(1):51. PubMed ID: 28476135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical and microbiological utility of inhaled aztreonam lysine for the treatment of acute pulmonary exacerbations of cystic fibrosis: An open-label randomised crossover study (AZTEC-CF).
    Frost F; Young GR; Wright L; Miah N; Smith DL; Winstanley C; Walshaw MJ; Fothergill JL; Nazareth D
    J Cyst Fibros; 2021 Nov; 20(6):994-1002. PubMed ID: 33358119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.
    Elborn JS; Henig NR
    Expert Opin Pharmacother; 2010 Jun; 11(8):1373-85. PubMed ID: 20426707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.
    Retsch-Bogart GZ; Quittner AL; Gibson RL; Oermann CM; McCoy KS; Montgomery AB; Cooper PJ
    Chest; 2009 May; 135(5):1223-1232. PubMed ID: 19420195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis.
    Oermann CM; Retsch-Bogart GZ; Quittner AL; Gibson RL; McCoy KS; Montgomery AB; Cooper PJ
    Pediatr Pulmonol; 2010 Nov; 45(11):1121-34. PubMed ID: 20672296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled aztreonam lysine: an evidence-based review.
    Hutchinson D; Barclay M; Prescott WA; Brown J
    Expert Opin Pharmacother; 2013 Oct; 14(15):2115-24. PubMed ID: 23992352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis.
    Parkins MD; Elborn JS
    Expert Rev Respir Med; 2010 Aug; 4(4):435-44. PubMed ID: 20658904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial.
    Assael BM; Pressler T; Bilton D; Fayon M; Fischer R; Chiron R; LaRosa M; Knoop C; McElvaney N; Lewis SA; Bresnik M; Montgomery AB; Oermann CM;
    J Cyst Fibros; 2013 Mar; 12(2):130-40. PubMed ID: 22985692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis.
    Elborn JS; Vataire AL; Fukushima A; Aballea S; Khemiri A; Moore C; Medic G; Hemels ME
    Clin Ther; 2016 Oct; 38(10):2204-2226. PubMed ID: 27692977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis. An economic evaluation.
    Schechter MS; Trueman D; Farquharson R; Higuchi K; Daines CL
    Ann Am Thorac Soc; 2015 Jul; 12(7):1030-8. PubMed ID: 26053185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa.
    Wainwright CE; Quittner AL; Geller DE; Nakamura C; Wooldridge JL; Gibson RL; Lewis S; Montgomery AB
    J Cyst Fibros; 2011 Jul; 10(4):234-42. PubMed ID: 21441078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis.
    Nick JA; Moskowitz SM; Chmiel JF; Forssén AV; Kim SH; Saavedra MT; Saiman L; Taylor-Cousar JL; Nichols DP
    Ann Am Thorac Soc; 2014 Mar; 11(3):342-50. PubMed ID: 24476418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood mRNA biomarkers distinguish variable systemic and sputum inflammation at treatment initiation of inhaled antibiotics in cystic fibrosis: A prospective non-randomized trial.
    Caceres SM; Sanders LA; Rysavy NM; Poch KR; Jones CR; Pickard K; Fingerlin TE; Marcus RA; Malcolm KC; Taylor-Cousar JL; Nichols DP; Nick JA; Strand M; Saavedra MT
    PLoS One; 2022; 17(5):e0267592. PubMed ID: 35511761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.